Novel therapeutic targets for cholestatic and fatty liver disease.

FGF19 is also an attractive therapeutic target in NASH ( table 1 ) where NGM282/aldafermin, significantly reduced hepatic fat content, serum aminotransferase levels and non-invasive fibrosis markers while histological improvement of fibrosis or resolution of NASH did not reach statistical significance after 24 weeks of treatment. 136 Interestingly, enrichment of Veillonella, a BA-sensitive bacteria whose enrichment is enabled by NGM282/aldafermin, may be a marker for therapeutic response. 137 Side effects of NGM282 are mostly of gastrointestinal origin but also include increases in LDL-cholester

also in 111,027 other papers